Marked responses to pemetrexed chemotherapy for metastatic adenocarcinoma of the parotid gland: Case series
| Autor: | Katharine A. Price, Paul V. Viscuse |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Oncology medicine.medical_specialty medicine.medical_treatment Antineoplastic Agents Pemetrexed Adenocarcinoma 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Neoplasm Invasiveness 030212 general & internal medicine Neoplasm Metastasis Bone pain Chemotherapy Salivary gland business.industry Cancer Middle Aged medicine.disease Parotid Neoplasms Parotid gland medicine.anatomical_structure Otorhinolaryngology 030220 oncology & carcinogenesis Female Salivary Gland Adenocarcinoma medicine.symptom business medicine.drug |
| Zdroj: | Head & Neck. 41:E99-E103 |
| ISSN: | 1097-0347 1043-3074 |
| DOI: | 10.1002/hed.25658 |
| Popis: | Background There are no proven systemic therapies for metastatic adenocarcinoma of the salivary glands. Pemetrexed use in adenocarcinoma of the salivary glands has not been previously described. Methods Retrospective case reports and literature review. Results Two patients with metastatic salivary gland adenocarcinoma were treated with single-agent pemetrexed with marked response and clinical benefit. Case 1 describes a sustained clinical response for 8 months after failing several lines of chemotherapy. Case 2 describes a marked interval response of diffuse metastatic disease at 2 months with resolution of bone pain and sustained response at 8 months. Conclusion To our knowledge, this is the first report of efficacy of single-agent pemetrexed for metastatic salivary gland adenocarcinoma. Given the significant and sustained responses in heavily pretreated patients, further investigation of pemetrexed for salivary cancer may be warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text